Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E13.17 EPS (ttm)3.75 Insider Own0.04% Shs Outstand2.79B Perf Week-2.55%
Market Cap137.95B Forward P/E13.27 EPS next Y3.72 Insider Trans-5.58% Shs Float2.79B Perf Month-5.80%
Income10.78B PEG3.40 EPS next Q0.91 Inst Own75.50% Short Float1.07% Perf Quarter-10.31%
Sales39.77B P/S3.47 EPS this Y176.90% Inst Trans-0.03% Short Ratio2.67 Perf Half Y-14.02%
Book/sh16.20 P/B3.05 EPS next Y4.14% ROA10.50% Target Price60.53 Perf Year-13.76%
Cash/sh4.33 P/C11.41 EPS next 5Y3.87% ROE22.90% 52W Range44.91 - 60.19 Perf YTD-6.51%
Dividend1.84 P/FCF223.57 EPS past 5Y-6.30% ROI16.40% 52W High-17.96% Beta0.67
Dividend %3.73% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin63.70% 52W Low9.95% ATR1.27
Employees70000 Current Ratio1.60 Sales Q/Q-4.60% Oper. Margin16.10% RSI (14)40.88 Volatility2.64% 2.48%
OptionableYes Debt/Eq0.58 EPS Q/Q106.50% Profit Margin27.10% Rel Volume1.51 Prev Close48.59
ShortableYes LT Debt/Eq0.53 EarningsFeb 03 BMO Payout47.10% Avg Volume11.21M Price49.38
Recom2.50 SMA20-2.82% SMA50-5.13% SMA200-9.20% Volume16,879,322 Change1.63%
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-05-16 05:00PM  ImmunoGen/Merck Collaborate for Ovarian Cancer Study
03:40PM  Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again? at Motley Fool
01:19PM  A Checkup On A Big Healthcare ETF
11:32AM  Merck & Co., Inc. Earnings Analysis: 2015 By the Numbers
09:27AM  FDA staff supports Celltrion's biosimilar Remicade Reuters
09:20AM  String of Q4 Earnings Beat Fails to Revive Pharma ETFs
07:56AM  FDA reviewers support Celltrion's biosimilar Remicade Reuters
Feb-04-16 06:16PM  2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried at Motley Fool
03:30PM  Cerus Corp. May Have Treatment For Zika Virus at Investopedia
02:29PM  Its Time to Buy This Biotech Gem
08:25AM  Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda at bizjournals.com
08:00AM  FDA Approves Mercks Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC) Business Wire
07:50AM  Emerging Situations, Growth Study - Analyst Notes on Apple, Merck & Co, Wal Mart Stores and Home Depot Accesswire
12:05AM  What Were the Overall Trends in Large-Cap Mutual Funds Last Year?
Feb-03-16 05:18PM  Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations
04:41PM  Merck and Chipotle are big market movers
04:08PM  Edited Transcript of MRK earnings conference call or presentation 3-Feb-16 1:00pm GMT
03:43PM  [$$] Merck Revenue and Profit Fall at The Wall Street Journal
01:49PM  Germanys Manufacturing Activity Cooled in January
01:43PM  Merck Drops On Light Q4 Sales, Full-Year Guidance at Barrons.com
12:27PM  Merck: A Leg Up In The Cancer Drug Race at The Wall Street Journal
12:16PM  International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results at Motley Fool
11:43AM  Merck beats 4Q profit forecast, misses Street view on sales
11:32AM  Eli Lilly and Co.s 4Q15 Earnings: An Overview
10:17AM  Merck Tops on Q4 Earnings, Revenue Outlook Falls Short
10:02AM  The Real Risks of Gileads Stock
09:53AM  Gilead Sciences: 'For Value Investors Who Seek Contrarian Ideas' at Barrons.com
09:39AM  Stocks Bounce as Labor Market Shows Resilience at TheStreet
09:12AM  Merck gives cautious 2016 outlook as sales of top medicines lag
09:01AM  Merck (MRK) Stock Declines in Pre-Market Trading on Q4 Revenue Miss at TheStreet
08:45AM  Merck Trips Up Over Mixed Earnings at 24/7 Wall St.
08:42AM  Shares Of Merck Dip Lower Following Q4 Print
08:22AM  Merck's (MRK) Q4 Earnings Beat Estimates
08:00AM  Merck Receives Approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the Treatment of Chronic Hepatitis C for Patients with Genotype 1, 3, or 4 Infection Following Priority Review CNW Group
08:00AM  Merck & Co Inc Earnings Call scheduled for 8:00 am ET today
07:58AM  Early movers: CMCSA, GM, MRK, MRVL, BDX & more at CNBC
07:40AM  Merck's revenue misses on lower drug sales, strong dollar
07:37AM  Morning Movers: Alexion, Merck Drop on Earnings; Atwood Oceanics Gains at Barrons.com
07:27AM  Wall Street gets a boost, again driven by oil at CNBC
07:27AM  Pfizer, J&J, Merck evaluating technologies for Zika vaccine
07:07AM  Q4 2015 Merck & Co Inc Earnings Release - Before Market Open
06:57AM  MERCK & CO., INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
06:45AM  Merck's Top-Selling Diabetes Drugs Miss Sales Estimates at Bloomberg
06:45AM  Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results Business Wire
12:00AM  Seven $1 billion-plus drugs seen reaching market in 2016 Reuters
Feb-02-16 08:00PM  What's Ahead For Wednesday: Investors Keep an Eye on Comcast at TheStreet
06:35PM  Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street
03:39PM  Health care analyst: How to play the current biotech market ahead of earnings
02:29PM  What to Watch in the Day Ahead - Wednesday, Feb 3 Reuters
01:19PM  Business events scheduled for Wednesday
12:20PM  Why Gilead Sciences Shares Tumbled 18% in January at Motley Fool
12:07PM  Gilead Sciences: It's Almost Earnings Time at Barrons.com
11:55AM  Merck (MRK) Stock Declines Before Wednesday's Earnings at TheStreet
10:18AM  Merck, Sanofi Exploring Potential End To Joint Venture In Europe
08:44AM  Should You Buy Merck (MRK) Ahead of Earnings?
07:57AM  Will Gilead Follow The Pfizer Game Plan For Sales Growth? at Forbes
07:44AM  Forget Merck & Co. Inc.: Here Are 2 Better Dividend Stocks at Motley Fool
Feb-01-16 07:08PM  Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
04:07PM  Novartis Reports Operational Growth in 4Q15
03:56PM  3 Numbers That Matter When Merck Reports Its Fourth-Quarter Results at Motley Fool
03:26PM  Gilead Faces its Greatest Threat to its Hepatitis C Drug: How Will That Impact Earnings?
11:16AM  Will 2016 Be Merck & Co. Inc.'s Best Year Yet? at Motley Fool
10:40AM  Monsanto CIO Jim Swanson Leads A Digital Revolution Of The World's Oldest Industry at Forbes
10:38AM  Earnings: Pharma Tends to Top Street EstimateCan PFE, MRK Repeat?
10:31AM  Gilead Sciences: 'An Increasingly Tight Hep C Space Moving Forward,' Guggenheim Says at Barrons.com
10:13AM  Earnings: Dollar Could Dent Pharma; Energy Hit by Crude's Drop at Forbes
06:01AM  Adversity Creates Opportunity
Jan-31-16 07:21PM  Mixed Earnings Expectations For Merck And Pfizer
10:10AM  Top 3 Dow Earnings for the Coming Week at 24/7 Wall St.
Jan-30-16 10:50AM  5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet at 24/7 Wall St.
Jan-29-16 06:55PM  Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
04:50PM  AbbVie Reports Mixed Q4 As Merck Launches Rival HCV Treatment
03:49PM  AstraZenecas 4Q15 Revenue Estimates: Expect a Fall!
03:26PM  Why is Gilead (GILD) Stock Falling Today?
02:21PM  3 Big Stocks You Might Want to Stay Away From Right Now at TheStreet
01:45PM  Merck Throws a Wrench in Drug Pricing at Bloomberg
01:40PM  Payers see price leverage with entry of Merck hepatitis C drug Reuters
01:32PM  Gilead Hits New 52-Week Low; Here Are Two Reasons Why
01:00PM  Is this a sucker's bottom?
12:58PM  Top trades for the 2nd half: Earnings ahead
12:21PM  Here's Why Gilead (GILD) Stock is Down Today at TheStreet
12:17PM  Gilead is Cheaper Than in 2008 and Six More Reasons to Buy at Barrons.com
11:54AM  Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space? at Motley Fool
11:43AM  [$$] Merck launches hepatitis C drug price war at Financial Times
11:29AM  Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient
11:28AM  With Merck Approval, Hepatitis-C Price War Back On at Barrons.com
10:58AM  FDA OKs Mercks new hepatitis C drug at MarketWatch
10:33AM  Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon at Motley Fool
08:16AM  Merck Takes on Gilead With Sharply Lower Hepatitis C Drug Price at TheStreet
Jan-28-16 09:06PM  FDA Approves Merck's New Hepatitis C Treatment at The Wall Street Journal
07:32PM  FDA OKs Merck hepatitis C drug, adding to patient choices
07:15PM  Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review at noodls
07:00PM  Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review PR Newswire
06:59PM  Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review Business Wire
06:16PM  Merck Hepatitis C Drug to Enter Crowded Field With High Prices at Bloomberg
06:10PM  U.S. FDA approves Merck's new hepatitis C pill Reuters
03:58PM  CDXS and LOGI are Aggressive Growth Stocks
03:50PM  A Small-Cap Biotech With Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen Marketwired
12:29PM  Pfizer vs. Merck -- Which Is the Better Dividend Stock Right Now? at TheStreet
11:48AM  Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA'
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. It has a strategic collaboration with Bionomics Limited. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM